# Equivalence of Resorption of Empagliflozin/Metformin Administered as Combination Tablet Compared With Empagliflozin/Metformin as Single Tablets Administered Together

> **NCT01811953** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 48 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Empagliflozin
- **DRUG:** Metformin
- **DRUG:** Empagliflozin
- **DRUG:** Empagliflozin/Metformin
- **DRUG:** Metformin
- **DRUG:** Empagliflozin/Metformin
- **DRUG:** Empagliflozin
- **DRUG:** Metformin
- **DRUG:** Empagliflozin/Metformin

## Key facts

- **NCT ID:** NCT01811953
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-03
- **Primary completion:** 2013-05
- **Final completion:** 2013-05
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2015-07-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01811953

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01811953, "Equivalence of Resorption of Empagliflozin/Metformin Administered as Combination Tablet Compared With Empagliflozin/Metformin as Single Tablets Administered Together". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01811953. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*